Farnier M.,Point Medical Rond Point
Medecine des Maladies Metaboliques | Year: 2013
When it became apparent that elevated concentration of plasma cholesterol was a major risk factor for atherosclerotic cardiovascular diseases, the search for new drugs reducing plasma cholesterol and more specifically LDL cholesterol (LDL-C) has been initiated. HMG-CoA reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway, was a natural target to reduce cholesterol biosynthesis and by consequence LDL-C. This paper describes the discovery and the development of HMG-CoA reductase inhibitors, named statins. © 2013 Elsevier Masson SAS. - Tous droits réservés.